Literature DB >> 25091475

Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.

Kwang Il Kim1, Su Jin Jang1, Ju Hui Park1, Yong Jin Lee1, Tae Sup Lee1, Kwang Sun Woo1, Hyun Park1, Jae Gol Choe2, Gwang Il An3, Joo Hyun Kang3.   

Abstract

UNLABELLED: Copper is an essential cofactor for a variety of biochemical processes including oxidative phosphorylation, cellular antioxidant activity, and elimination of free radicals. The copper transporter 1 is known to be involved in cellular uptake of copper ions. In this study, we evaluated the utility of human copper transporter 1 (hCTR1) gene as a new reporter gene for (64)Cu PET imaging.
METHODS: Human breast cancer cells (MDA-MB-231) were infected with a lentiviral vector constitutively expressing the hCTR1 gene under super cytomegalovirus promoter, and positive clones (MDA-MB-231-hCTR1) were selected. The expression of hCTR1 gene in MDA-MB-231-hCTR1 cells was measured by reverse transcription polymerase chain reaction, Western blot, and (64)Cu uptake assay. To evaluate the cytotoxic effects induced by hCTR1 expression, the dose-dependent cell survival rate after treatment with cisplatin (Cis-diaminedichloroplatinum (II) [CDDP]) was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and trypan blue dye exclusion. Small-animal PET images were acquired in tumor-bearing mice from 2 to 48 h after an intravenous injection of (64)Cu.
RESULTS: The hCTR1 gene expression in MDA-MB-231-hCTR1 cells was confirmed at the RNA and protein expression and the cellular (64)Cu uptake level. MTT assay and trypan blue dye exclusion showed that the cell viability of MDA-MB-231-hCTR1 cells decreased more rapidly than that of MDA-MB-231 cells after treatment with CDDP for 96 or 72 h, respectively. Small-animal PET imaging revealed a higher accumulation of (64)Cu in MDA-MB-231-hCTR1 tumors than in MDA-MB-231 tumors. With respect to the biodistribution data, the percentage injected dose per gram of (64)Cu in the MDA-MB-231 tumors and MDA-MB-231-hCTR1 tumors at 48 h after (64)Cu injection was 2.581 ± 0.254 and 5.373 ± 1.098, respectively.
CONCLUSION: An increase in (64)Cu uptake induced by the expression of hCTR1 gene was demonstrated in vivo and in vitro, suggesting the potential use of hCTR1 gene as a new imaging reporter gene for PET with (64)CuCl2.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  64Cu; PET; cisplatin; hCTR1; reporter gene

Mesh:

Substances:

Year:  2014        PMID: 25091475     DOI: 10.2967/jnumed.114.141127

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Cyclotron Production of High-Specific Activity 55Co and In Vivo Evaluation of the Stability of 55Co Metal-Chelate-Peptide Complexes.

Authors:  Tara Mastren; Bernadette V Marquez; Deborah E Sultan; Elizabeth Bollinger; Paul Eisenbeis; Tom Voller; Suzanne E Lapi
Journal:  Mol Imaging       Date:  2015       Impact factor: 4.488

Review 2.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

Review 3.  Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma.

Authors:  Jason Wachsmann; Fangyu Peng
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer.

Authors:  Orit Jacobson; Xuefeng Yan; Gang Niu; Ido D Weiss; Ying Ma; Lawrence P Szajek; Baozhong Shen; Dale O Kiesewetter; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2015-02-19       Impact factor: 10.057

Review 5.  Recent Advances in Cancer Imaging with 64CuCl2 PET/CT.

Authors:  Fangyu Peng
Journal:  Nucl Med Mol Imaging       Date:  2022-02-17

Review 6.  Connecting copper and cancer: from transition metal signalling to metalloplasia.

Authors:  Eva J Ge; Ashley I Bush; Angela Casini; Paul A Cobine; Justin R Cross; Gina M DeNicola; Q Ping Dou; Katherine J Franz; Vishal M Gohil; Sanjeev Gupta; Stephen G Kaler; Svetlana Lutsenko; Vivek Mittal; Michael J Petris; Roman Polishchuk; Martina Ralle; Michael L Schilsky; Nicholas K Tonks; Linda T Vahdat; Linda Van Aelst; Dan Xi; Peng Yuan; Donita C Brady; Christopher J Chang
Journal:  Nat Rev Cancer       Date:  2021-11-11       Impact factor: 69.800

7.  Preclinical PET imaging study of lung cancer with 64CuCl2.

Authors:  Qiang Wang; Dongli Song; Xiaowei Ma; Xiaodong Wu; Lei Jiang
Journal:  Ann Nucl Med       Date:  2020-06-21       Impact factor: 2.668

8.  Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications.

Authors:  Sergio Righi; Martina Ugolini; Gianluca Bottoni; Matteo Puntoni; Massimiliano Iacozzi; Francesco Paparo; Manlio Cabria; Luca Ceriani; Monica Gambaro; Luca Giovanella; Arnoldo Piccardo
Journal:  EJNMMI Res       Date:  2018-03-01       Impact factor: 3.138

9.  Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma.

Authors:  Clément Bailly; Sébastien Gouard; Michel Chérel; Caroline Bodet-Milin; Marie Lacombe; Patricia Remaud-Le Saëc; Benjamin Chalopin; Mickaël Bourgeois; Nicolas Chouin; Raphaël Tripier; Zakaria Halime; Ferid Haddad; Alain Faivre-Chauvet; Françoise Kraeber-Bodéré
Journal:  Oncotarget       Date:  2018-01-03

10.  Nano-graphene oxide composite for in vivo imaging.

Authors:  Sung-Chan Jang; Sung-Min Kang; Jun Young Lee; Wan-Seob Cho; Seo Yeong Oh; At Ezhil Vilian; Ilsong Lee; Young-Kyu Han; Jeong Hoon Park; Changhyun Roh; Yun Suk Huh
Journal:  Int J Nanomedicine       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.